Treatment of patients with mild to moderate hypercholesterolemia: Lipoprotein and Coronary Atherosclerosis Study (LCAS)

Cardiovascular Reviews and Reports

Volumn 19, Issue 1, 1998, Pages 12-24

  Ballantyne, Christie M ^a   Herd, J Alan ^a   Schein, Jeffrey R ^b   Jones, Peter H ^a   Farmer, John A ^a   Gotto Jr , Antonio M ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUINDOSTATIN;

CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; DRUG EFFECT; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; REVIEW;

EID: 6844252244     PISSN: 01973118     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Sacks FM, Pasternak RC, Gibson CM, et al. Effect on coronaryatherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Lancet. 1994;344: 1182-1186.
2. Sacks FM, Pfeffer MA, Moye LA, et al, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels, N Engl J Med. 1996;335: 1001-1009.
3. West MS, Herd JA, Ballantyne CM, et al, for the LCAS Investigators. The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia. Control Clin Trials. 1996;17:550-583.
4. Expert Panel. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med. 1988;148:36-69.
5. Reiber JHC, Serruys PW, Kooijman CJ, et al Assessment of short-, medium-, and long-term variations in arterial dimensions from computer-assisted quantitation of coronary cineangiograms Circulation. 1985;71:280-288.
6. Herd JA, Ballantyne CM, Farmer JA, et al, for the LCAS Investigators. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol. 1997;80:278-286.
7. Herd JA, West MS, Ballantyne CM, et al. Beneficial effects of fluvastatin on clinical cardiac and all fatal events in patients with mild cholesterol elevations [abstract]. J Investig Med. 1997;45:222A.
8. Ballantyne CM, Herd JA, West MS, et al. Influence of low HDL-C on progression of CAD and response to fluvastatin therapy [abstract]. J Am Coll Cardiol. 1997;29:232A.
9. Herd JA, West MS, Ferlic I., Ballantyne CM, Gotto AM Jr. Influence of age and sex on angiographie change in the Lipoprotein and Coronary Atherosclerosis Study (LCAS) [abstract]. J Am Coll Cardiol. 1997;29:139A.
10. Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation. 1994;89:959-968.
11. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
12. Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med. 1993;119:969-976.
13. Pitt B, Mancini GBJ, Ellis SG, Rosman HS, Park J-S, McGovern ME, for the PLAC I Investigators. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC I): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol. 1995;26:1133-1139.
14. Jukema JW, Bruschke AVG, van Boven AJ, et al., on behalf of the REGRESS Study Group. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Staun Study (REGRESS). Circulation. 1995;91: 2528-2540.
15. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet. 1994;344:633-638.
16. Buchwald H, Matts JP, Fitch LL, et al., for the Program on the Surgical Control of the Hyperlipidemias (POSCH) Group. Changes in sequential coronary arteriograms and subsequent coronary events. JAMA. 1992;268:1429-1433.
17. Waters D, Craven TE, Lespérance J. Prognostic significance of progression of coronary atherosclerosis. Circulation. 1993;87: 1067-1075.
18. Azen SP, Mack WJ, Cashin-Hemphill L, et al. Progression of coronary artery disease predicts clinical coronary events: long-term follow-up from the Cholesterol Lowering Atherosclerosis Study. Circulation. 1996;93:34-41.
19. Rossouw JE. Lipid-lowering interventions in angiographic trials. Am J Cardiol. 1995;76:86C-92C.
20. Sacks FM, Gibson CM, Rosner B, et al. The influence of pretreatment low density lipoprotein cholesterol concentrations on the effect of hypocholesterolemic therapy on coronary atherosclerosis in angiographic trials. Am J Cardiol. 1995;76 (9 suppl):78C-85C.
21. National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 1994;89:1329-1445.